Keywords: USA, FDA, Post-marketing surveillance, Blue Spoon

Working with US FDA’s Sentinel Initiative: a framework to adapt systemically to market evolution

Article | 15 January 2010

A strategy for the pharmaceutical industry to “sense and respond” to unpredictable effects associated with proactive risk surveillance by the ...

Enjoying this article? To continue reading you need to login or subscribe.

Subscribe now
for unlimited access to all articles

Subscriptions are £60 per month, pay as you go.
Find out more details.

Already a subscriber? Click here to log in